Showing results (591-600 of 2,229) with videos related to
Sort By:
Pageof 223
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2011
A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cellsYao-Wu Du, Ju-Gao Chen, Hui-Ling Bai, et al.Cancer Biotherapy & Radiopharmaceuticals|May 5, 2011
CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumorSujuan Yuan, Tiankui Qiao, Wei ChenCancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Image-guided percutaneous (125)I seed implantation as a salvage treatment for recurrent soft tissue sarcomas after surgery and radiotherapyJinna Li, Junjie Wang, Na Meng, et al.Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.Cancer Biotherapy & Radiopharmaceuticals|December 3, 2011
Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonasPing Jiang, Yuliang Jiang, Jun-jie Wang, et al.Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.Cancer Biotherapy & Radiopharmaceuticals|February 27, 2009
Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat?Frits Aarts, Thijs Hendriks, Annemarie Eek, et al.Cancer Biotherapy & Radiopharmaceuticals|February 27, 2009
Adenovirus-mediated wild-type p53 transfer radiosensitizes H1299 cells to subclinical-dose carbon-ion irradiation through the restoration of p53 functionBing Liu, Hong Zhang, Xin Duan, et al.Cancer Biotherapy & Radiopharmaceuticals|February 27, 2009
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitroGyula KulcsárCancer Biotherapy & Radiopharmaceuticals|February 27, 2009
A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stressDanyi Li, Yuechun Zhu, Qiongling Tang, et al.Pageof 223